<code id='A59D5B6BC8'></code><style id='A59D5B6BC8'></style>
    • <acronym id='A59D5B6BC8'></acronym>
      <center id='A59D5B6BC8'><center id='A59D5B6BC8'><tfoot id='A59D5B6BC8'></tfoot></center><abbr id='A59D5B6BC8'><dir id='A59D5B6BC8'><tfoot id='A59D5B6BC8'></tfoot><noframes id='A59D5B6BC8'>

    • <optgroup id='A59D5B6BC8'><strike id='A59D5B6BC8'><sup id='A59D5B6BC8'></sup></strike><code id='A59D5B6BC8'></code></optgroup>
        1. <b id='A59D5B6BC8'><label id='A59D5B6BC8'><select id='A59D5B6BC8'><dt id='A59D5B6BC8'><span id='A59D5B6BC8'></span></dt></select></label></b><u id='A59D5B6BC8'></u>
          <i id='A59D5B6BC8'><strike id='A59D5B6BC8'><tt id='A59D5B6BC8'><pre id='A59D5B6BC8'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:9
          Janet Woodcock -- health policy coverage from STAT
          Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

          WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

          Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

          advertisement

          Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Midwives could help bridge maternal health disparities in the U.S.
          Midwives could help bridge maternal health disparities in the U.S.

          HANNAHMCKAY/POOL/AFPviaGettyImagesInthewakeofgrowingalarmoverthedisproportionatelyhighratesofmaterna

          read more
          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more

          ProMED sees offers of support, but its future remains unclear

          ProMEDmapScreengrabviaProMEDWithitsfutureindoubt,ProMED,thefinanciallystrappedinfectiousdiseasessurv